Pharmacological prevention of post-ERCP pancreatitis-An everlasting dream?

Digestive and Liver Disease

Volumn 38, Issue 8, 2006, Pages 596-598

  Hellmig, S ^a   Folsch U R ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALLOPURINOL; AMYLASE; ANTIBIOTIC AGENT; APROTININ; BETA CAROTENE; BOTULINUM TOXIN; BRADYKININ; CALCITONIN; CONTRAST MEDIUM; DICLOFENAC; GABEXATE MESILATE; GLUCAGON; GLYCERYL TRINITRATE; HEPARIN; HYDROLASE; INTERLEUKIN 10; LIDOCAINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PANCREAS ENZYME; SECRETIN; SOMATOSTATIN; STEROID;

ABDOMINAL PAIN; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT DISEASE; CLINICAL TRIAL; COMMON BILE DUCT STONE; COST EFFECTIVENESS ANALYSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GASTROINTESTINAL ENDOSCOPY; HIGH RISK PATIENT; HUMAN; HYPERAMYLASEMIA; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; PANCREAS DISEASE; PANCREATITIS; RISK FACTOR; RISK REDUCTION; SYMPTOM;

EID: 33748483624     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.04.005     Document Type: Note

References (33)

1. Rabinov K.R., and Simon M. Peroral cannulation of the ampulla of Vater for direct cholangiography and pancreatography. Preliminary report of a new method. Radiology 85 (1965) 693-697
2. McCune W.S., Shorb P.E., and Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. Ann Surg 167 (1968) 752-756
3. Classen M., and Demling L. Endoscopic sphincterotomy of the papilla of Vater and extraction of stones from the choledochal duct (author's transl). Dtsch Med Wochenschr 99 (1974) 496-497
4. Kawai K., Akasaka Y., Murakami K., Tada M., and Koli Y. Endoscopic sphincterotomy of the ampulla of Vater. Gastrointest Endosc 20 (1974) 148-151
5. Pieper-Bigelow C., Strocchi A., and Levitt M.D. Where does serum amylase come from and where does it go?. Gastroenterol Clin North Am 19 (1990) 793-810
6. Pezzilli R., Romboli E., Campana D., and Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. J Pancreas 3 (2002) 162-168
7. Arvanitidis D., Anagnostopoulos G.K., Giannopoulos D., Pantes A., Agaritsi R., Margantinis G., et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 19 (2004) 278-282
8. Binmoeller K.F., Harris A.G., Dumas R., Grimaldi C., and Delmont J.P. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?. Gut 33 (1992) 1129-1133
9. Brust R., Thomson A.B., Wensel R.H., Sherbaniuk R.W., and Costopoulos L. Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. Gastrointest Endosc 24 (1977) 77-79
10. Budzynska A., Marek T., Nowak A., Kaczor R., and Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 33 (2001) 766-772
11. Deviere J., Le Moine O., Van Laethem J.L., Eisendrath P., Ghilain A., Severs N., et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 120 (2001) 498-505
12. Gorelick A., Barnett J., Chey W., Anderson M., and Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 36 (2004) 170-173
13. Lavy A., Karban A., Suissa A., Yassin K., Hermesh I., and Ben-Amotz A. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 29 (2004) e45-e50
14. Moreto M., Zaballa M., Casado I., Merino O., Rueda M., Ramirez K., et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: a randomized double-blind trial. Gastrointest Endosc 57 (2003) 1-7
15. Murray B., Carter R., Imrie C., Evans S., and O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124 (2003) 1786-1791
16. Odes H.S., Novis B.N., Barbezat G.O., and Bank S. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 16 (1977) 180-184
17. Ohashi A., Tamada K., Tomiyama T., Wada S., Higashizawa T., Gotoh Y., et al. Epinephrine irrigation for the prevention of pancreatic damage after endoscopic balloon sphincteroplasty. J Gastroenterol Hepatol 16 (2001) 568-571
18. Poon R.T., Yeung C., Liu C.L., Lam C.M., Yuen W.K., Lo C.M., et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 52 (2003) 1768-1773
19. Prat F., Amaris J., Ducot B., Bocquentin M., Fritsch J., Choury A.D., et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 56 (2002) 202-208
20. Rabenstein T., Roggenbuck S., Framke B., Martus P., Fischer B., Nusko G., et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?. Gastrointest Endosc 55 (2002) 476-483
21. Raty S., Sand J., Pulkkinen M., Matikainen M., and Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 5 (2001) 339-345 [discussion 345]
22. Schwartz J.J., Lew R.J., Ahmad N.A., Shah J.N., Ginsberg G.G., Kochman M.L., et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 59 (2004) 179-184
23. Silvis S.E., and Vennes J.A. The role of glucagon in endoscopic cholangiopancreatography. Gastrointest Endosc 21 (1975) 162-163
24. Sudhindran S., Bromwich E., and Edwards P.R. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 88 (2001) 1178-1182
25. Testoni P.A., Cicardi M., Bergamaschini L., Guzzoni S., Cugno M., Buizza M., et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 42 (1995) 301-305
26. Testoni P.A., Mariani A., Masci E., and Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral center without and with routine prophylaxis with gabexate: a 6-year survey. Dig Liver Dis 38 (2006)
27. Andriulli A., Clemente R., Solmi L., Terruzzi V., Suriani R., Sigillito A., et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 56 (2002) 488-495
28. Andriulli A., Solmi L., Loperfido S., Leo P., Festa V., Belmonte A., et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2 (2004) 713-718
29. Cavallini G., Tittobello A., Frulloni L., Masci E., Mariana A., and Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 335 (1996) 919-923
30. Di Francesco V., Mariani A., Angelini G., Masci E., Frulloni L., Talamini G., et al. Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Dig Dis Sci 47 (2002) 741-745
31. Masci E., Cavallini G., Mariani A., Frulloni L., Testoni P.A., Curioni S., et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 98 (2003) 2182-2186
32. Pezzilli R., Gabbrielli A., Labate A.M., D'Alessio P., Barakat B., Costamagna G., et al. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?. Hepatogastroenterology 50 (2003) 851-855
33. Tympner F., and Rosch W. Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP. Z Gastroenterol 20 (1982) 688-693